Challenge to AstraZeneca's Cancer Drug as Synlogic's TY-9591 Outperforms Osimertinib
On March 9, Synlogic announced that its self-developed drug TY-9591 has successfully outperformed AstraZeneca's renowned lung cancer treatment, Osimertinib, in a pivotal Phase II clinical trial.
Founded in 2017, Synlogic is an innovative pharmaceutical company set to go public on the Hong Kong Stock Exchange in August 2024. TY-9591, a deuterated variant of Osimertinib, is the company's lead pipeline candidate.
Market reaction to this announcement was swift, interpreting it as a significant challenge to Osimertinib, which is widely regarded as a "miracle drug" for lung cancer. On March 10, Synlogic's stock surged by over 40% in early trading, ultimately closing with a 16.18% increase.
In response to this emerging competitor, AstraZeneca stated on March 11 that it could not provide feedback due to the limited information currently available from the study.
Osimertinib, the world's first third-generation EGFR-TKI drug, was approved in the U.S. in 2015 and entered the Chinese market in 2017. It has consistently generated robust sales, reaching nearly $5.8 billion globally in 2023. Even with the arrival of domestic third-generation EGFR-TKI drugs, Osimertinib has maintained a dominant position, controlling around 80% of the small molecule targeted lung cancer drug market in China.
Notably, Osimertinib's compound patent will not expire until 2032.
Synlogic's strategy involves deuterated modifications to Osimertinib. This approach is considered one of the least risky and most straightforward methods to enhance existing drugs. Domestic companies like Zai Lab and HEC Group have also focused on deuterated drugs, with Zai Lab's Donafenib being a notable example that was approved in 2021.
In terms of indications, Synlogic is targeting lung cancer with brain metastases, a critical factor affecting the survival of lung cancer patients. The occurrence of brain metastases is significantly higher in patients with EGFR mutations, with risks ranging from 40% to 60%. Osimertinib is recognized for its effectiveness in managing brain metastases, contributing to its success in head-to-head trials.
While Synlogic has not disclosed specific Phase II data, it reported that the trial enrolled 224 patients, achieving the primary endpoint of intracranial objective response rate (iORR). More detailed results are expected to be shared at upcoming international or domestic clinical conferences.
The announcement has sparked both enthusiasm and skepticism within the industry. Critics have raised questions about Synlogic's choice of objective response rate as the primary endpoint, arguing that it does not align with industry standards and differs from AstraZeneca's original trial design.
In a previous instance in September 2024, another company, Kangfang Biopharma, claimed a decisive victory in a head-to-head trial against Merck's Keytruda based on multiple data points, but lacked overall survival data, prompting a cautious response from Merck.
Osimertinib's rise to first-line treatment status was largely due to its achievement of significant median progression-free survival (PFS) data. For patients with brain metastases, Osimertinib demonstrated a PFS increase from 9.6 months to 15.2 months, solidifying its reputation as a leading treatment.
Although Synlogic has reported an impressive 100% iORR in its single-agent treatment for non-small cell lung cancer with brain metastases, this single data point alone may not be sufficient to sway the medical community, and consensus will depend on comprehensive results.
In the competitive landscape, Osimertinib faces challenges not only from Synlogic but also from several other third-generation EGFR-TKI drugs that have recently entered the market. Companies like Betta Pharmaceuticals and Bayer are already exploring fourth-generation TKIs, and Johnson & Johnson's dual-antibody combination has received FDA approval.
As Osimertinib stands firm against this growing competition, it is clear that strong clinical data is just one aspect of maintaining its market position. This is a critical factor that Synlogic and other competitors must take into account.
On March 11, Synlogic's stock declined nearly 9%, resulting in a market capitalization decrease of over HKD 1 billion.
2026-11-15
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Dow Swings from an $801 Million Loss to an $802 Million Profit as Hormuz Disruption Lifts Polyethylene Prices
-
Türkiye Advances $3 Billion Petrochemical Cluster Targeting 17% of Domestic Polypropylene Demand
-
BASF Evaluates New MDI Production Complex in India, Secures Dahej Site
-
Covestro Builds New 660,000-ton MDI Plant in China: Global Supply Gap Meets Chinese Overcapacity Head-On
-
“An €8 Billion Loss, Yet a 25% Price Hike”: Wacker Chemie’s Contradictory Crisis—Survival Move or Desperate Gamble?
-
“The C Empire Unites!”: Wanhua Chemical’s $26.5 Billion Bet on Ethylene Integration—Is It Becoming China’s BASF or the New Global Olefins Overlord?
-
US Chemical Shutdown Wave Expands, PS Units Become the Hardest Hit Segment
-
Lotte Chemical Plans Sale of Selected Operations in Malaysia, Indonesia, and the United States
-
Dafeng Haijianuo’s RMB 246 Million Technical Revamp Project Takes Shape, with Multiple Production Lines for Vitamin K1, Folic Acid, and Others Under Construction
-
BASF Approves €1 Billion Share Buyback Program as Chemical Giant Prioritizes Capital Discipline
Recommend Reading
-
$12 Billion Merger! A New North American Chemical Giant Is About to Be Born
-
BASF and Encina Bet on Circular Chemical Feedstocks
-
RMB 30 Billion Olefins Project Issues Second EIA Public Notice; Fuhai Removes Five Units
-
Henkel Plans to Acquire Swiss Adhesive Specialist ATP Adhesive Systems, Expanding Its Sustainable Tape Portfolio
-
350 Million Yuan! Shandong Huayang Dr Chemical Industry Co., Ltd.'s Nitric Acid Expansion in Ningyang, Tai'an
-
Raw Material Prices Continue to Rise, Anhydrous Hydrogen Fluoride Market Remains Firm in China (12.8-12.12)
-
Recent Acetic Acid Market Trends Show Strong Upward Momentum in China
-
This week, the price of polyester bottle chips in China showed a slight decline
-
August 10, 2026—Xinol Market Outlook
-
rket Outlook for Maleic Anhydride on August 25, 2026: Volatile